Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD
+9.54 (1.27%)
At close: Dec 1, 2022 4:00 PM
+3.41 (0.45%)
After-hours: Dec 1, 2022 7:19 PM EST
Market Cap 81.86B
Revenue (ttm) 13.71B
Net Income (ttm) 5.37B
Shares Out 106.90M
EPS (ttm) 3.98
PE Ratio 191.27
Forward PE 17.48
Dividend n/a
Ex-Dividend Date n/a
Volume 670,027
Open 756.19
Previous Close 751.7
Day's Range 752.41 - 768.53
52-Week Range 538.01 - 769.63
Beta 0.20
Analysts Buy
Price Target 791.92 (+4.0%)
Earnings Date Nov 3, 2022

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection t... [Read more]

Industry Biotechnology
IPO Date Apr 2, 1991
CEO Leonard Schleifer
Employees 10,915
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2021, REGN's revenue was $16.07 billion, an increase of 89.14% compared to the previous year's $8.50 billion. Earnings were $8.08 billion, an increase of 129.86%.

Financial Statements

Analyst Forecast

According to 34 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 791.92, which is an increase of 4.03% from the latest price.

Price Target
(4.03% upside)
Analyst Consensus: Buy
Stock Forecasts


Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review

The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.

18 hours ago - Zacks Investment Research

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types

Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in advanced non-small cell lung cancer TARRYTOWN, N.Y. , Dec. 1, 2022...

21 hours ago - PRNewsWire

Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Prio...

If approved, Evkeeza would be the first and only treatment of its kind to help children as young as 5 years old control dangerously high levels of LDL cholesterol caused by homozygous familial hyperchol...

1 day ago - PRNewsWire

2 Market-Beating Stocks That Can Continue Rising in 2023

It's not too late to get in on the potential 2023 growth for these two stocks.

Other symbols: TMUS
1 day ago - The Motley Fool

7 Undervalued Biotech Stocks to Buy Before They Boom

You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.

2 days ago - InvestorPlace

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

6 days ago - Zacks Investment Research

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals. The post Dexcom Leads 5 Stocks Near Buy Points appeared first on Investor's Business Daily.

Other symbols: DXCMCBEQTRBC
6 days ago - Investors Business Daily

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

1 week ago - Zacks Investment Research

Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Meta...

Approval based on a Phase 3 trial that demonstrated significant survival benefit in patients with recurrent or metastatic cervical cancer, with Libtayo reducing the risk of death by 31% compared to chem...

1 week ago - PRNewsWire

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics fo...

Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody® and Regeneron's Veloci-Bi ® platforms CytomX to receive $30 million upfron...

Other symbols: CTMX
2 weeks ago - PRNewsWire

2 Top Biotech Stocks to Buy in November

Both of these companies have potential catalysts on the way.

Other symbols: GILD
2 weeks ago - The Motley Fool

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularis If approved, Dupixe...

2 weeks ago - PRNewsWire

Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemothera...

3 weeks ago - Zacks Investment Research

Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced ...

Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC indi...

3 weeks ago - PRNewsWire

Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular...

Presentations reinforce that aflibercept 8 mg demonstrated non-inferior vision gains to EYLEA at 48 weeks, with 93% and 83% of patients in PHOTON and PULSAR, respectively, maintaining dosing intervals o...

3 weeks ago - PRNewsWire

7 Cash-Rich Stocks to Buy for Peace of Mind

Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes thei...

3 weeks ago - InvestorPlace

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y. , Nov. 3, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:15 p.m.

4 weeks ago - PRNewsWire

Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent

Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.

4 weeks ago - Zacks Investment Research

Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders

First Phase 2 data for odronextamab (CD20xCD3) in diffuse large B-cell lymphoma and follicular lymphoma to be presented in two oral sessions Additional presentations include new data on linvoseltamab (R...

4 weeks ago - PRNewsWire

Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall

Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.

4 weeks ago - Investors Business Daily

Regeneron Pharmaceuticals Q3 tops earnings and revenue marks

Regeneron Pharmaceuticals Inc. REGN, -2.56% said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from $1.63 billion or $14.33 a share, in the year-ago period. Adjusted...

4 weeks ago - Market Watch

Regeneron Reports Third Quarter 2022 Financial and Operating Results

Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV ® (a)(b), revenues increased 11% Third quarter 2022 EYLEA® U.S. net sales increased 11% versus t...

4 weeks ago - PRNewsWire

Final Trades: Boeing, Amazon, Regeneron & more

The "Halftime Report" traders give their top picks to watch for the second half.

1 month ago - CNBC Television

Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Prod...

Inmazeb is the first FDA-approved treatment for Zaire ebolavirus TARRYTOWN, N.Y. , Oct. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ (atoltivimab...

1 month ago - PRNewsWire